Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO
12:00am, Thursday, 06'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
ABIOMED, Inc. (NASDAQ: ABMD)
Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) (announced a U.S. government grant for a...
Cambridge Investment Research Advisors Inc. Has $1.52 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)
06:52am, Wednesday, 05'th Aug 2020
Cambridge Investment Research Advisors Inc. trimmed its position in Exelixis, Inc. (NASDAQ:EXEL) by 1.1% in the second quarter, Holdings Channel.com reports. The firm owned 63,957 shares of the biotec
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
First Quadrant L P CA Makes New $401,000 Investment in Exelixis, Inc. (NASDAQ:EXEL)
09:22am, Saturday, 01'st Aug 2020
First Quadrant L P CA bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) during the 2nd quarter, Holdings Channel reports. The firm bought 16,910 shares of the biotechnology company’s s
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
04:33pm, Thursday, 30'th Jul 2020
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exelixis to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020
08:05pm, Wednesday, 29'th Jul 2020
Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 after the markets close. At 5:30 p.m. EDT / 2:30 p.m. PDT, Exe
Will Exelixis (EXEL) Gain on Rising Earnings Estimates?
04:20pm, Thursday, 23'rd Jul 2020
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
EXEL vs. RGEN: Which Stock Should Value Investors Buy Now?
03:40pm, Wednesday, 22'nd Jul 2020
EXEL vs. RGEN: Which Stock Is the Better Value Option?
Osmotica PDUFA, And Other News: The Good, Bad And Ugly Of Biopharma
10:09am, Wednesday, 22'nd Jul 2020
Osmotica Pharmaceuticals receives PDUFA date. Exelixis initiates pivotal Phase 3 study for Cabozantinib.
Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive?
04:10pm, Tuesday, 21'st Jul 2020
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exelixis Starts Study on Cabometyx Combo in Kidney Cancer
02:00pm, Tuesday, 21'st Jul 2020
Exelixis (EXEL) initiates CONTACT-03, a global phase III pivotal study of Cabometyx (cabozantinib) in combination with Roche's Tecentriq.
Could The Exelixis, Inc. (NASDAQ:EXEL) Ownership Structure Tell Us Something Useful?
04:43pm, Monday, 20'th Jul 2020
If you want to know who really controls Exelixis, Inc. (NASDAQ:EXEL), then you'll have to look at the makeup of its...
Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with
Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination
$231.23 Million in Sales Expected for Exelixis, Inc. (NASDAQ:EXEL) This Quarter
01:52am, Saturday, 18'th Jul 2020
Wall Street analysts expect that Exelixis, Inc. (NASDAQ:EXEL) will announce $231.23 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Exelixis’
